AB009. OS02.03. Phase II trial of cetuximab and chemotherapy followed by surgical resection for locally advanced thymoma

James Huang1, Dan Raz2, Mihaela Cristea3, Kristina Deonaraine1, Amelia Starr1, William Travis4, Michelle Ginsberg5, David Jones1, Valerie Rusch1, Mark Kris6, Gregory Riely6

1Department of Surgery, Memorial Sloan Kettering Cancer, New York, NY, USA; 2Department of Surgery, 3Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA; 4Department of Pathology, 5Department of Radiology, 6Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA

Background: The mainstay of treatment for thymoma is surgery with neoadjuvant chemotherapy recommended to patients with locally advanced disease. EGFR is overexpressed in thymoma. Clinical responses to single-agent cetuximab have been reported in patients with advanced cetuximab. We conducted this two-site prospective phase II trial of cetuximab combined with a standard induction chemotherapy regimen of cisplatin, doxorubicin and cyclophosphamide (PAC) in patients with locally advanced thymoma prior to surgical resection.

Methods: Patients with clinical Masaoka stage III–IVA thymoma were treated with cetuximab (250 mg/m² weekly ×4 weeks) followed by cetuximab (250 mg/m² weekly) combined with cisplatin (50 mg/m²), doxorubicin (50 mg/m²) and cyclophosphamide [(500 mg/m²) 3 weeks ×4 cycles]. Radiographic response was assessed by CT using RECIST 1.1 and FDG-PET using PERCIST. All patients went on to surgery after completion of induction therapy. The primary endpoint was major pathologic response (MPR, >90% treatment effect). Planned enrollment was 18 patients in first stage of a two stage design. If 1 MPR was observed, then enrollment would expand to 28 patients.

Results: Eighteen patients were enrolled: 8 women, median age 53 (range, 32–73) years. WHO Histologic subtype A: 2, AB: 3, B1: 3, B2: 7, B3: 3. Final Masaoka stage I: 2, II: 2, III: 5, IVA: 9. There were no responses to cetuximab alone by RECIST criteria, although 1 patient had a 25% reduction in indicator lesions. Response rate (CR + PR), in evaluable patients after complete treatment course was 50% (8/16, 95% CI: 28–72%). Partial responses by PERCIST criteria were seen on PET in 11/18 (61%) evaluable patients. There were no MPRs. R0 resection was obtained in 7 patients; 5 had R1 and 6 had R2 resections.

Conclusions: The addition of cetuximab to PAC chemotherapy did not lead to pathologic complete responses in the neoadjuvant setting. Cetuximab alone appears to have little effect during 4 weeks of treatment. There was no apparent increase in radiographic response rate with the addition of cetuximab to PAC chemotherapy compared to historical series.

Keywords: Chemotherapy; cetuximab; thymoma

doi: 10.21037/med.2017.AB009